MSI-H/ MMRd

我们是谁

  • 1 月 17, 2024
    Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
  • 1 月 17, 2024
    Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Refractory BRAF V600E mCRC
  • 1 月 17, 2024
    ZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer
  • 1 月 17, 2024
    阿美单抗与抗 PD-1 单克隆抗体和 FOLFIRI 联合用于 RAS 野生型晚期结直肠癌患者的研究
  • 1 月 17, 2024
    Clinical Study on the Efficacy of Autologous Cell Factor Induced Killer Cells in the Treatment of Colorectal Cancer
  • 1 月 17, 2024
    COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
  • 1 月 17, 2024
    In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung
  • 1 月 12, 2024
    A Study of QBECO Versus Placebo in the Treatment of Colorectal Cancer That Has Spread to the Liver
  • 1 月 12, 2024
    联合免疫疗法方案的 I/II 期研究：治疗转移性结直肠癌 (mCRC) 的联合免疫疗法方案：SX-682、TriAdeno 疫苗、雷替凡利单抗和 IL-15 激动剂 N-803 (STAR15)
  • 1 月 10, 2024
    评估INCB099280对免疫检查点抑制剂无效的特定实体瘤患者的作用的研究